Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting.

Abstract

[125I]P2 exhibits high affinity and selectivity for the alpha(v)beta3 integrin in vitro and in vivo and, thus, represents the first radiolabeled alpha(v)beta3 antagonist for the investigation of angiogenesis and metastasis in vivo.